Benjamin Klein, J. Michelle Kahlenberg, Johann E. Gudjonsson
{"title":"Proteins lead the way: JAK inhibitors as a new treatment option in toxic epidermal necrolysis","authors":"Benjamin Klein, J. Michelle Kahlenberg, Johann E. Gudjonsson","doi":"10.1038/s41392-024-02122-6","DOIUrl":null,"url":null,"abstract":"<p>In a recent study, published in <i>Nature</i>, Nordmann et al. identified Janus kinase inhibitors (JAKi) as a new treatment option for life-threatening toxic epidermal necrolysis (TEN). They showed this through spatial proteomics on human skin samples combined with in vivo administration of JAKi in individuals with TEN, demonstrating rapid reepithelization and recovery of patients.<sup>1</sup> As TEN has a high mortality rate (30–50%),<sup>2</sup> this study offers a new avenue for targeted treatment.</p>","PeriodicalId":21766,"journal":{"name":"Signal Transduction and Targeted Therapy","volume":"30 1","pages":""},"PeriodicalIF":40.8000,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Signal Transduction and Targeted Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41392-024-02122-6","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
In a recent study, published in Nature, Nordmann et al. identified Janus kinase inhibitors (JAKi) as a new treatment option for life-threatening toxic epidermal necrolysis (TEN). They showed this through spatial proteomics on human skin samples combined with in vivo administration of JAKi in individuals with TEN, demonstrating rapid reepithelization and recovery of patients.1 As TEN has a high mortality rate (30–50%),2 this study offers a new avenue for targeted treatment.
期刊介绍：
Signal Transduction and Targeted Therapy is an open access journal that focuses on timely publication of cutting-edge discoveries and advancements in basic science and clinical research related to signal transduction and targeted therapy.
Scope: The journal covers research on major human diseases, including, but not limited to:
Cancer,Cardiovascular diseases,Autoimmune diseases,Nervous system diseases.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
